Epcoritamab - CISMeF

Preferred Label : Epcoritamab;

NCIt synonyms : DuoBody-CD3xCD20; Anti-CD20/CD3 Bispecific Antibody GEN3013; Epcoritamab-bysp;

NCIt definition : A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.;

UNII : D6OMY2L0WA;

CAS number : 2134641-34-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2134641-34-0 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Epkinly;

Molecule name : GEN-3013; GEN 3013;

NCI Metathesaurus CUI : CL973375;

Codes from synonyms : 66092;

Origin ID

C163022;

UMLS CUI

C5418281;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD20 [NCIt concept]
is_component_of_chemotherapy_regimen
- Epcoritamab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Details

Main resources

You can consult :